Compounds and methods for treating bacterial infections

Patent metadata

Field	Value
Publication number	US-9957289-B2
Application number	US-201414894927-A
Country	US
Kind code	B2
Filing date	May 30, 2014
Priority date	May 30, 2013
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

The present invention encompasses compounds and methods for treating and preventing bacterial infections specifically urinary tract infections and those caused by bacteria containing type 1 pili and FimH. The present invention also encompasses compounds and methods for treating inflammatory bowel disease specifically Crohn's Disease.

First claim

What is claimed is:

1. A compound, the compound comprising Formula (IV):

wherein:
X is selected from the group consisting of hydrogen and OR 2 ;
R 2 is independently selected from the group consisting of hydrogen, PO(OH) 2 , acetyl, COR 5 , CO(OR 5 ), CO(CH 2 ) n NR 5 R 6 , hydrocarbyl and substituted hydrocarbyl;
n is an integer from 1 to 10;
Z is O;
Y is selected from the group consisting of O, CH(OH), CH(OR 5 ), CHNR 5 R 6 , CH 2 , S, and NR 5 ;
R 1 is selected from the group consisting of CH 3 , CF 3 , halogen, Cl, F, Br, I, OH, NH 2 , NR 5 R 6 , OCH 3 , CO 2 CH 3 , CONHCH 3 , alkyl, cyclopropyl, OR 5 , CO 2 R 5 , CONR 5 R 6 , hydrocarbyl, and substituted hydrocarbyl;
R 5 is selected from the group consisting of H and an optionally substituted alkyl, aryl, heterocycle, and cycloalkyl;
R 6 and R 7 are selected from the group consisting of an optionally substituted alkyl, cycolalkyl, aryl, and heterocycle;
R 8 and R 11 are independently selected from the group consisting of CONHCH 3 , COOCH 3 , COOH, CONH(heterocycle), heterocycle, H, alkyl, cyclopropyl, aryl, OR 5 , NR 5 R 6 , NR 5 COR 6 , NR 5 COOR 6 , NR 5 CONR 6 , NR 5 SO 2 R 6 , COR 5 , SO 2 R 5 , halogen, CN, NO 2 , COOR 5 , CONR 5 R 6 , NCOR 7 , NCONR 7 , NCOOR 7 , SO 2 NR 5 R 6 , and NHSO 2 R 7 ;
R 12 is selected from the group consisting of H, alkyl, CH 2 R 13 , CH 2 COR 13 , CH 2 CONHR 13 , CH 2 CONHR 13 R 14 , CH 2 CONH(CH 2 ) 2 R 14 , (CH 2 ) 2 NR 13 , (CH 2 ) n NR 13 , CH 2 COOH, CH 2 CONH(CH 2 ) 2 NH 2 , and (CH 2 ) 2 N(CH 3 ) 2 ;
R 13 is selected from the group consisting of —OH and an optionally substituted heterocycle, hydrocarbyl, and substituted hydrocarbyl;
R 14 is selected from the group consisting of alkyl and NH 2 .

2. A method of treating a urinary tract infection, the method comprising administering a compound of claim 1 to a subject in need thereof.

3. The method of claim 2 , wherein the subject is further administered a bactericidal composition.

4. A method of preventing a urinary tract infection, the method comprising administering a compound of claim 1 to a subject in need thereof.

5. The method of claim 4 , wherein the subject is further administered a bactericidal composition.

6. A method of reducing the resistance of a bacterium to a bactericidal compound, the method comprising administering a compound of claim 1 to a subject in need thereof.

7. A method of treating inflammatory bowel disease, the method comprising administering a compound of claim 1 to a subject in need thereof.

8. The method of claim 7 , wherein the inflammatory bowel disease is Crohn's disease.

9. The method of claim 7 , wherein treating comprises reducing symptoms associated with inflammatory bowel disease.

10. A method of inhibiting FimH binding to mannose, the method comprising contacting a compound of claim 1 with FimH, wherein the compound binds FimH and inhibits binding to mannose.

11. The method of claim 10 , wherein the mannose is exposed on a bladder cell.

12. The method of claim 10 , wherein the mannose is exposed on an intestinal cell.

13. A method of treating a catheter-associated urinary tract infection, the method comprising administering a compound of claim 1 to a subject in need thereof.

14. The compound of claim 1 , wherein the compound is selected from the group consisting of:

Assignees

• Univ Washington

Inventors

• Janetka James W
• Han Zhenfu
• Hultgren Scott
• Pinkner Jerry
• Cusumano Corinne

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P13/02

  of urine or of the urinary tract, e.g. urine acidifiers · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title